ArticleDiabetes care2016
Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia.
Article in Diabetes care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.The Cochrane database of systematic reviews · 2018Pooled it
- Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis.PloS one · 2017Pooled it
- Efficacy and safety of needle-free injection in patients with type 2 diabetes mellitus undergoing intensive insulin therapy: a randomized controlled trial based on the flash glucose monitoring system.Frontiers in endocrinology · 2025Trial
- Effects of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: results from the OmniCarb trial.Diabetic medicine : a journal of the British Diabetic Association · 2017Trial
- 1,5-Anhydroglucitol: From Short-Term Glycemic Monitoring to Risk Stratification of Diabetes Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Use of Fructosamine for Glycemic Monitoring in Patients With Sickle Cell Disease and Diabetes: A Systematic Review.Cureus · 2025Review
- The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications.Frontiers in endocrinology · 2024Review
- Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.Diabetes care · 2023Review
- Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.Clinical chemistry · 2023Article
- Serum fructosamine and glycemic status in the presence of the sickle cell mutation.Diabetes research and clinical practice · 2021Article
- Factors associated with glycated albumin in adults without diabetes.Medicine and pharmacy reports · 2021Article
- Prediabetes and What It Means: The Epidemiological Evidence.Annual review of public health · 2021Review
- Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease.Diabetes care · 2020Observational
- Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring.Diabetes technology & therapeutics · 2019 · on this mapArticle
- An Update on Measures of Preoperative Glycemic Control.Plastic and reconstructive surgery. Global open · 2019Article
- Article
- Issues in Defining the Burden of Prediabetes Globally.Current diabetes reports · 2018Review
- Haemoglobin A1c or Glycated Albumin for Diagnosis and Monitoring Diabetes: An African Perspective.Indian journal of clinical biochemistry : IJCB · 2018Review
- Are There Clinical Implications of Racial Differences in HbA1c? A Difference, to Be a Difference, Must Make a Difference.Diabetes care · 2016Article
- Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment.Ophthalmology scienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveWe compared levels and associations of traditional (fasting glucose, HbA1c) and nontraditional (fructosamine, glycated albumin, and 1,5-anhydroglucitol [1,5-AG]) biomarkers of hyperglycemia with incident cardiovascular disease (CVD), incident end-stage renal disease (ESRD), and prevalent retinopathy in black and white adults. RESEARCH DESIGN AND
methodsWe included 10,373 participants without (8,096 white, 2,277 black) and 727 with diagnosed diabetes (425 white, 302 black) from the Atherosclerosis Risk in Communities (ARIC) Study. We used Cox proportional hazards models to compare hazards ratios of CVD and ESRD among blacks and whites from baseline (1990-1992) through 2012. We compared the odds ratios (from logistic regression) of retinopathy among blacks and whites. We tested for the interaction of each biomarker with race.
resultsMedian values of biomarkers were higher among blacks versus whites (all P < 0.001). Relative risks for each biomarker with incident CVD and ESRD, and odds ratios for each biomarker with prevalent retinopathy, were similar by race (all P values for interaction by race >0.10).
conclusionsThe prognostic value of HbA1c, fructosamine, glycated albumin, and 1,5-AG with incident CVD, incident ESRD, and prevalent retinopathy were similar by race. Our results support similar interpretation of HbA1c and nontraditional biomarkers of hyperglycemia among black and whites with respect to long-term complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.